In a study in AML [7], 100% of patients with long-term complete remission showed high FADD levels in leukemic cells, while 82% of those patients exhibiting chemotherapy resistance or relapse showed reduced FADD levels. The gene discussed is FADD; the disease is acute myeloid leukemia.